Sample Page

2MePI, also known as 2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole, is a serotonin receptor modulator of the pyridoindole (γ-carboline) family.^[1] It is the pyridoindole homologue of the ibogalog (azepinoindole) ibogaminalog (DM-506).^[1]

The drug acts as a weak partial agonist or functional competitive antagonist of the serotonin 5-HT_2A receptor, with an affinity (K_i) of 95 nM, an EC₅₀Tooltip half-maximal effective concentration (E_maxTooltip maximal efficacy) of 533 nM (32%), an apparent IC₅₀Tooltip half-maximal inhibitory concentration of 3,100 to 18,000 nM, and a K_B of 89 to 228 nM.^[1] Compared to ibogaminalog, 2MePi had 5-fold lower affinity, 59-fold lower activational potency, and less than half the activational efficacy at the serotonin 5-HT_2A receptor.^[1] Results were analogous for 8MeO-2MePI against ibogainalog (8MeO-2MePI’s ibogalog homologue).^[1] These findings indicate that ibogalogs are the more optimal structural scaffold for serotonin 5-HT_2A receptor agonism.^[1]

2MePI was first described in the scientific literature by Matthias Liechti and colleagues in 2026.^[1]

• Substituted γ-carboline
• Pyridopyrroloquinoxaline § Related compounds
• Tiflucarbine